{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-011546","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2026-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.607492+00:00","generated_at":"2026-05-15T07:01:55.502971+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulse Biosciences enrolls first 7 patients in NANOPULSE-AF pivotal trial for nPulse AFib catheter","bullets":["First 7 patients treated at St. Bernards Medical Center by Devi Nair, MD.","Study plans to enroll ~215 participants across multiple sites; endpoints at 6 and 12 months.","Prior feasibility study showed 96% procedural success at 12 months and 100% acute success.","nPulse catheter uses nanosecond pulsed field ablation, integrated with Abbott EnSite X mapping.","Company aims to evaluate safety and efficacy for drug-resistant paroxysmal AF."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-011546","json":"https://secwatch.observer/filing/0001437749-26-011546.json","markdown":"https://secwatch.observer/filing/0001437749-26-011546.md","text":"https://secwatch.observer/filing/0001437749-26-011546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926011546/0001437749-26-011546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926011546/plse20260406_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:01:55.502971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}